CIM
ARCT icon

Cambria Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

Cambria Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,557
Closed -$281K – 340
2024
Q2 		$281K Sell
11,557
-2,961
-20% -$89.8K 0.02% 325
2024
Q1 		$490K Sell
14,518
-331
-2% -$11.7K 0.03% 209
2023
Q4 		$468K Buy
14,849
+249
+2% +$5.92K 0.03% 196
2023
Q3 		$373K Sell
14,600
-2,555
-15% -$78.7K 0.03% 204
2023
Q2 		$492K Buy
+17,155
New +$467K 0.04% 182

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambria Investment Management's ARCT Position: Q3 2024 in Review

Cambria Investment Management sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 11,557 shares — an estimated $281K sold.

Cambria Investment Management first reported a position in ARCT in Q2 2023 and held it in 5 quarters. The position peaked at $492K in Q2 2023. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Cambria Investment Management reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cambria Investment Management sold 11,557 Arcturus Therapeutics shares in Q3 2024, an estimated $281K.
  • Cambria Investment Management first reported a position in Arcturus Therapeutics in Q2 2023 and held it in 5 quarters.
  • Cambria Investment Management's Arcturus Therapeutics position peaked at $492K in Q2 2023.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Cambria Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.